Literature DB >> 21885676

Characterization of a new mouse model of empyema and the mechanisms of pleural invasion by Streptococcus pneumoniae.

Sylwia Wilkosz1, Lindsey A Edwards, Silvia Bielsa, Catherine Hyams, Abigail Taylor, Robert J O Davies, Geoffrey J Laurent, Rachel C Chambers, Jeremy S Brown, Y C Gary Lee.   

Abstract

Although empyema affects more than 65,000 people each year in the United States and in the United Kingdom, there are limited data on the pathogenesis of pleural infection. We investigated the pathogenesis of empyema using animal and cell culture models of Streptococcus pneumoniae infection. The pathological processes during the development of empyema associated with murine pneumonia due to S. pneumoniae (strain D39) were investigated. Lungs were examined using histology, and pleural fluid and blood bacterial colony-forming units, cytokine levels, and cellular infiltrate were determined over time. Bacterial migration across mesothelial monolayers was investigated using cell culture techniques, flow cytometry, and confocal microscopy. After intranasal inoculation with 10(7) S. pneumoniae D39 strain, mice developed pneumonia associated with rapid bacterial invasion of the pleural space; raised intrapleural IL-8, VEGF, MCP-1, and TNF-α levels; and caused significant intrapleural neutrophilia followed by the development of fibrinous pleural adhesions. Bacterial clearance from the pleural space was poor, and in vitro assays demonstrated that S. pneumoniae crossed mesothelial layers by translocation through cells rather than by a paracellular route. This study describes key events during the development of S. pneumoniae empyema using a novel murine model of pneumonia-associated empyema that closely mimics human disease. The model allows for future assessment of molecular mechanisms involved in the development of empyema and evaluation of potential new therapies. The data suggest that transmigration of bacteria through mesothelial cells could be important in empyema development. Furthermore, upon entry the pleural cavity offers a protected compartment for the bacteria.

Entities:  

Mesh:

Year:  2011        PMID: 21885676      PMCID: PMC3410914          DOI: 10.1165/rcmb.2011-0182OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  31 in total

1.  The effects of early chest tube placement on empyema resolution.

Authors:  S Sasse; T K Nguyen; M Mulligan; N S Wang; C K Mahutte; R W Light
Journal:  Chest       Date:  1997-06       Impact factor: 9.410

2.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

3.  Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.

Authors:  Zhiwen Zhu; Michael L Hawthorne; Yubiao Guo; Wonder Drake; Semra Bilaceroglu; Heather L Misra; Richard W Light
Journal:  Chest       Date:  2006-06       Impact factor: 9.410

4.  Thoracic empyema in patients with community-acquired pneumonia.

Authors:  Rabia A Ahmed; Thomas J Marrie; Jane Q Huang
Journal:  Am J Med       Date:  2006-10       Impact factor: 4.965

5.  Additive inhibition of complement deposition by pneumolysin and PspA facilitates Streptococcus pneumoniae septicemia.

Authors:  Jose Yuste; Marina Botto; James C Paton; David W Holden; Jeremy S Brown
Journal:  J Immunol       Date:  2005-08-01       Impact factor: 5.422

6.  Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions.

Authors:  Helen E Davies; Ross S Sadler; Silvia Bielsa; Nicholas A Maskell; Najib M Rahman; Robert J O Davies; Berne L Ferry; Y C Gary Lee
Journal:  Am J Respir Crit Care Med       Date:  2009-03-19       Impact factor: 21.405

7.  Pleural fluid transforming growth factor-beta1 correlates with pleural fibrosis in experimental empyema.

Authors:  Scott A Sasse; Martin R Jadus; Gary D Kukes
Journal:  Am J Respir Crit Care Med       Date:  2003-09-15       Impact factor: 21.405

8.  Identification of pneumococcal serotypes from culture-negative clinical specimens by novel real-time PCR.

Authors:  D Tarragó; A Fenoll; D Sánchez-Tatay; L A Arroyo; C Muñoz-Almagro; C Esteva; W P Hausdorff; J Casal; I Obando
Journal:  Clin Microbiol Infect       Date:  2008-09       Impact factor: 8.067

9.  U.K. Controlled trial of intrapleural streptokinase for pleural infection.

Authors:  Nicholas A Maskell; Christopher W H Davies; Andrew J Nunn; Emma L Hedley; Fergus V Gleeson; Robert Miller; Rhian Gabe; Glyn L Rees; Timothy E A Peto; Mark A Woodhead; Donald J Lane; Janet H Darbyshire; Robert J O Davies
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

10.  Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae.

Authors:  Jose Yuste; Marina Botto; Stephen E Bottoms; Jeremy S Brown
Journal:  PLoS Pathog       Date:  2007-09-28       Impact factor: 6.823

View more
  16 in total

1.  Differential Pneumococcal Growth Features in Severe Invasive Disease Manifestations.

Authors:  Marien I de Jonge; Amelieke J H Cremers; Daan W Arends; Wynand Alkema; Indri Hapsari Putri; Christa E van der Gaast-de Jongh; Marc Eleveld; Jeroen D Langereis; Quirijn de Mast; Jacques F Meis
Journal:  Microbiol Spectr       Date:  2022-06-09

2.  Targeting plasminogen activator inhibitor-1 in tetracycline-induced pleural injury in rabbits.

Authors:  Galina Florova; Ali O Azghani; Sophia Karandashova; Chris Schaefer; Serge V Yarovoi; Paul J Declerck; Douglas B Cines; Steven Idell; Andrey A Komissarov
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-31       Impact factor: 5.464

Review 3.  Pneumonia and empyema: causal, casual or unknown.

Authors:  Lindsay McCauley; Nathan Dean
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 4.  Pleural mesothelial cells in pleural and lung diseases.

Authors:  Hitesh Batra; Veena B Antony
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

5.  Pulmonary cytokine composition differs in the setting of alcohol use disorders and cigarette smoking.

Authors:  Ellen L Burnham; Elizabeth J Kovacs; Christopher S Davis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-19       Impact factor: 5.464

6.  Development of primary invasive pneumococcal disease caused by serotype 1 pneumococci is driven by early increased type I interferon response in the lung.

Authors:  Catherine E Hughes; Richard M Harvey; Charles D Plumptre; James C Paton
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

7.  Endothelial Cell Protein C Receptor Deficiency Attenuates Streptococcus pneumoniae-induced Pleural Fibrosis.

Authors:  Shiva Keshava; Jhansi Magisetty; Torry A Tucker; Weshely Kujur; Sachin Mulik; Charles T Esmon; Steven Idell; L Vijaya Mohan Rao; Usha R Pendurthi
Journal:  Am J Respir Cell Mol Biol       Date:  2021-04       Impact factor: 6.914

8.  Organizing empyema induced in mice by Streptococcus pneumoniae: effects of plasminogen activator inhibitor-1 deficiency.

Authors:  Torry A Tucker; Ann Jeffers; Jake Boren; Brandon Quaid; Shuzi Owens; Kathleen B Koenig; Yoshikazu Tsukasaki; Galina Florova; Andrey A Komissarov; Mitsuo Ikebe; Steven Idell
Journal:  Clin Transl Med       Date:  2016-05-13

9.  Host response to respiratory bacterial pathogens as identified by integrated analysis of human gene expression data.

Authors:  Steven B Smith; Michal Magid-Slav; James R Brown
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Dose dependency of outcomes of intrapleural fibrinolytic therapy in new rabbit empyema models.

Authors:  Andrey A Komissarov; Galina Florova; Ali O Azghani; Ann Buchanan; Jake Boren; Timothy Allen; Najib M Rahman; Kathleen Koenig; Mignote Chamiso; Sophia Karandashova; James Henry; Steven Idell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-24       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.